Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (1066)	3/28/2002 10:54:58 PM
From: Spekulatius	Respond to of 2243

OGSI I sniffed around some websites about Gaucher's disease before buying into OGSI. The Vavesca trials are commented and the users give it decent reviews. It is true that there are side effect (mostly GI) but there are also some patients who experience side effect with Cerezyme. I think there is a market for Vavesca even though it may be inferior to Cerezyme because of: 1) Vavesca being an oral drug 2) No backup to Cerezyme currently available 3) Cereyzme is excruatingly expensive I'd give it a 50% chance of approval but i think that OGSI is worth its current price even without Vavesca.